Abstract
Laboratory mice provide a ready source of diverse, high-affinity and high-specificity monoclonal antibodies (mAbs). However, development of rodent antibodies as therapeutic agents has been impaired by the inherent immunogenicity of these molecules. One technology that has been explored to generate low immunogenicity mAbs for in vivo therapy involves the use of transgenic mice expressing repertoires of human antibody gene sequences. This technology has now been exploited by over a dozen different pharmaceutical and biotechnology companies toward developing new therapeutic mAbs, and currently at least 33 different drugs in clinical testing—including several in pivotal trials—contain variable regions encoded by human sequences from transgenic mice. The emerging data from these trials provide an early glimpse of the safety and efficacy issues for these molecules. Nevertheless, actual product approval, the biggest challenge so far, is required to fully validate this technology as a drug discovery tool. In the future, it may be possible to extend this technology beyond rodents and use transgenic farm animals to directly generate and produce human sequence polyclonal sera.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Ris
Katie Ris
Katie Ris
Similar content being viewed by others
References
Pendley, C., Schantz, A. & Wagner, C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5, 172–179 (2003).
Goldstein, G. et al. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N. Engl. J. Med. 6, 337–342 (1985).
Kuus-Reichel, K. et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1, 365–372 (1994).
Baert, F. et al. Influence of immunogenicity on the long-term efficacy of imfliximab in Crohn's disease. N. Engl. J. Med. 348, 601–608 (2003).
Morrison, S. et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).
Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
McCafferty, J. et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990).
Larrick, J.W. & Bourla, J.M. Prospects for the therapeutic use of human monoclonal antibodies. J. Biol. Response Mod. 5, 379–393 (1986).
James, K. & Bell, G.T. Human monoclonal antibody production. Current status and future prospects. J. Immunol. Methods 100, 5–40 (1987).
Houghton, A.N. et al. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J. Exp. Med. 158, 53–65 (1983).
Olsson, L. et al. Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells. J. Exp. Med. 159, 537–550 (1984).
Dessain, S.K. et al. High efficiency creation of human monoclonal antibody-producing hybridomas. J. Immunol. Methods 291, 109–122 (2004).
Harris, J.F. et al. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J. Immunol. Methods 148, 199–207 (1992).
Traggiai, E. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871–875 (2004).
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Alt, F.W., Blackwell, T.K. & Yancopoulos, G.D. Immunoglobulin genes in transgenic mice. Trends Genet. 1, 231–236 (1985).
Bruggemann, M. et al. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc. Natl. Acad. Sci. USA 86, 6709–6713 (1989).
Mansour, S.L., Thomas, K.R. & Capecchi, M.R. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336, 348–352 (1988).
Zijlstra, M. et al. Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 342, 435–438 (1989).
Schwartzberg, P.L., Goff, S.P. & Robertson, E.J. Germ-line transmission of a c-abl mutation produced by targeted gene disruption in ES cells. Science 246, 799–803 (1989).
Lonberg, N. et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856–859 (1994).
Green, L.L. et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7, 13–21 (1994).
Taylor, L.D. et al. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int. Immunol. 6, 579–591 (1994).
Ignatovitch, O. et al. The creation of diversity in the human immunoglobulin V(lambda) repertoire. J. Mol. Biol. 268, 69–77 (1997).
Davis, M.M. The evolutionary and structural 'logic' of antigen receptor diversity. Semin. Immunol. 16, 239–243 (2004).
Tomlinson, I.M. et al. The imprint of somatic hypermutation on the repertoire of human germline V genes. J. Mol. Biol. 256, 813–817 (1996).
Xu, J.L. & Davis, M.M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13, 37–45 (2000).
Adderson, E.E. et al. Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations. J. Clin. Invest. 89, 729–738 (1992).
Ambrosino, D.M. et al. Correlation of the Km(1) immunoglobulin allotype with anti-polysaccharide antibodies in Caucasian adults. J. Clin. Invest. 78, 361–365 (1986).
Chung, G.H. et al. Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. V. In vivo expression of individual antibody clones is dependent on Ig CH haplotypes and the categories of antigen. J. Immunol. 151, 4352–4361 (1993).
Nadel, B. et al. Decreased frequency of rearrangement due to the synergistic effect of nucleotide changes in the heptamer and nonamer of the recombination signal sequence of the V kappa gene A2b, which is associated with increased susceptibility of Navajos to Haemophilus influenzae type b disease. J. Immunol. 161, 6068–6073 (1998).
Feeney, A.J. et al. A defective V kappa A2 allele in Navajos which may play a role in increased susceptibility to Haemophilus influenzae type b disease. J. Clin. Invest. 97, 2277–2282 (1996).
Moulton, L.H. et al. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int. J. Epidemiol. 29, 753–756 (2000).
Lucas, A.H., Larrick, J.W. & Reason, D.C. Variable region sequences of a protective human monoclonal antibody specific for the Haemophilus influenzae type b capsular polysaccharide. Infect. Immun. 62, 3873–3880 (1994).
Fishwild, D. et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845–851 (1996).
Mendez, M.J. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146–156 (1997).
Green, L.L. & Jakobovits, A. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J. Exp. Med. 188, 483–495 (1998).
Tomizuka, K. et al. Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat. Genet. 16, 133–143 (1997).
Tomizuka, K. et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc. Natl. Acad. Sci. USA 97, 722–727 (2000).
Kuroiwa, Y. et al. Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts. Nat. Biotechnol. 18, 1086–1090 (2000).
Popov, A.V. et al. A human immunoglobulin lambda locus is similarly well expressed in mice and humans. J. Exp. Med. 189, 1611–1620 (1999).
Nicholson, J.C. et al. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol. 163, 6898–6906 (1999).
Zou, Y.R., Muller, W., Gu, H. & Rajewsky, K. Cre-loxP-mediated gene replacement: a mouse strain producing humanized antibodies. Curr. Biol. 4, 1099–1103 (1994).
Zou, X. et al. Block in development at the pre-B-II to immature B cell stage in mice without Ig kappa and Ig lambda light chain. J. Immunol. 170, 1354–1361 (2003).
Ren, L. et al. Silencing of the immunoglobulin heavy chain locus by removal of all eight constant-region genes in a 200-kb region. Genomics 84, 686–695 (2004).
Harding, F.A. & Lonberg, N. Class switching in human immunoglobulin transgenic mice. Ann. NY Acad. Sci. 764, 536–546 (1995).
Ball, W.J. et al. Isolation and characterization of human monoclonal antibodies to digoxin. J. Immunol. 163, 2291–2298 (1999).
Farr, C.D. et al. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J. Med. Chem. 45, 3257–3270 (2002).
Tzipori, S. et al. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17, 926–941 (2004).
Mukherjee, J. et al. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70, 5896–5899 (2002).
Mukherjee, J. et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70, 612–619 (2002).
He, Y. et al. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169, 595–605 (2002).
Chang, Q. et al. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. 70, 4977–4986 (2002).
Maitta, R.W. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect. Immun. 72, 4810–4818 (2004).
Ishida, I. et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4, 91–102 (2002).
Villadsen, L.S. et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112, 1571–1580 (2003).
Bekker, P.J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059–1066 (2004).
Yang, X.D. et al. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. 66, 401–410 (1999).
Huang, S. et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161, 125–134 (2002).
Mian, B.M. et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin. Cancer Res. 9, 3167–3175 (2003).
Ostendorf, T. et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 14, 2237–2247 (2003).
Suarez, E. et al. Human monoclonal antibodies produced in transgenic BABkappa,lambda mice recognising idiotypic immunoglobulins of human lymphoma cells. Mol. Immunol. 41, 519–526 (2004).
Skov, L. et al. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 139, 1433–1439 (2003).
Fishwild, D. et al. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin. Immunol. 92, 138–152 (1999).
Teeling, J.L. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793–1800 (2004).
Schuler, W. et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77, 717–726 (2004).
Bleeker, W.K. et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173, 4699–4707 (2004).
Borchmann, P. et al. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma. Curr. Opin. Investig. Drugs 5, 1262–1267 (2004).
Rowinski, E.K. et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003–3015 (2004).
Cohen, B.D. et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11, 2063–2073 (2005).
Yang, X.-D. et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236–1243 (1999).
Yang, X.D. et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38, 17–23 (2001).
Holmes, E.H. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Investig. Drugs 10, 511–519 (2001).
Borchmann, P. et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102, 3737–3742 (2003).
Heuck, F. et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J. Immunother. 27, 347–353 (2004).
Ramakrishna, V. et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172, 2845–2852 (2004).
Keler, T. et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 171, 6251–6259 (2003).
Sanderson, K. et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23, 741–750 (2005).
Suzuki, N. et al. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecol. Oncol. 95, 290–298 (2004).
Imakiire, T. et al. Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int. J. Cancer 108, 564–570 (2004).
Mori, E. et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 11, 203–207 (2004).
Garambois, V. et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 4, 75 (2004).
Trikha, M. et al. CNTO 95, a fully human monoclonal antibody that inhibits alpha v integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110, 326–335 (2004).
Nozawa, S. et al. HMMC-1: a humanized monoclonal antibody with therapeutic potential against Mullerian duct-related carcinomas. Clin. Cancer Res. 10, 7071–7078 (2004).
Foote, J. & Eisen, H. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92, 1254–1256 (1995).
Roost, H.P. et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl. Acad. Sci. USA 92, 1257–1261 (1995).
Foon, K.A. et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58, 984–990 (2004).
Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
Calvo, E. & Rowinsky, E.K. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr. Oncol. Rep. 7, 96–103 (2005).
Phan, G.Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).
Ribas, A. et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 27, 354–367 (2004).
Robinson, M.R. et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. 27, 478–479 (2004).
Hodi, F.S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100, 4712–4717 (2003).
Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Mannon, P.J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069–2079 (2004).
Hermeling, S. et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897–903 (2004).
Kraj, P. et al. The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. J. Immunol. 158, 5824–5832 (1997).
Kline, G.H. et al. Pre-B cell receptor-mediated selection of pre-B cells synthesizing functional mu heavy chains. J. Immunol. 161, 1608–1618 (1998).
Ivanov, I., Link, J., Ippolito, G.C. & Schroeder, H.W. Jr. Constraints on the hydropathicity and sequence composition of HCDR3 are conserved across evolution. in The Antibodies, vol. 7 (eds. Zanetti, M. & Capra, J.D.) 43–67 (Taylor and Francis, London, 2002).
Helms, L.R. & Wetzel, R. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Protein Sci. 4, 2073–2081 (1995).
Rose, V.L. & Gordon, L.I. Idiopathic thrombocytopenic purpura in pregnancy. Successful management with immunoglobulin infusion. J. Am. Med. Assoc. 254, 2626–2628 (1985).
MacDonald, P.S. et al. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation–increased morbidity with OKT3. Transplantation 55, 110–116 (1993).
Kuroiwa, Y. et al. Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol. 20, 889–894 (2002).
Kuroiwa, Y. et al. Sequential targeting of the genes encoding immunoglobulin-mu and prion protein in cattle. Nat. Genet. 36, 775–780 (2004).
Acknowledgements
I thank Don Drakeman for comments and Michelle Temple for assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author is an employee of, and has a financial interest, in Medarex, Inc.
Rights and permissions
About this article
Cite this article
Lonberg, N. Human antibodies from transgenic animals. Nat Biotechnol 23, 1117–1125 (2005). https://doi.org/10.1038/nbt1135
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1135
This article is cited by
-
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Nature Reviews Drug Discovery (2023)
-
Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases—RA as a role model
Inflammation and Regeneration (2022)
-
Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci
Nature Communications (2022)
-
The interaction analysis between human serum albumin with chlorpyrifos and its derivatives through sub-atomic docking and molecular dynamics simulation techniques
3 Biotech (2022)
-
Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line
Cellular & Molecular Immunology (2021)